DNA demethylation and cancer metastasis: Therapeutic implications

Expert Opinion on Drug Discovery

Volumn 3, Issue 5, 2008, Pages 519-531

  Szyf, Moshe ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Decitabine; DNA demethylase; DNA demethylation; DNA methylation; DNA methylation inhibitors; Epigenetic therapy; Epigenome; Global hypomethylation; Histone acetylation; Hypermethylated CG islands; MBD2; Methyl rich diets; Prometastatic genes; SAM; Tumor suppressor genes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; DNA; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 1 INHIBITOR; DNA METHYLTRANSFERASE INHIBITOR; FOLIC ACID; HISTONE DEACETYLASE INHIBITOR; METHYL CPG BINDING PROTEIN 2; MG 98; TRICHOSTATIN A;

ALCOHOL CONSUMPTION; ANTINEOPLASTIC ACTIVITY; BIOTRANSFORMATION; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RISK; CLINICAL TRIAL; COLORECTAL CARCINOMA; DEMETHYLATION; DNA HYPOMETHYLATION; DNA METABOLISM; DNA METHYLATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME ACTIVITY; EPIGENETICS; EVIDENCE BASED MEDICINE; FOLIC ACID DEFICIENCY; GENE ACTIVATION; GENE SILENCING; HEMATOLOGIC MALIGNANCY; HUMAN; KIDNEY METASTASIS; LOW DRUG DOSE; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; METASTASIS POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SMOKING; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; UPREGULATION;

EID: 44649201531     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.5.519     Document Type: Review

References (135)

1. Weinberg RA. The molecular basis of oncogenes and tumor suppressor genes. Ann NY Acad Sci 1995;758:331-8
2. Razin A. CpG methylation, chromatin structure and gene silencing-a three-way connection. EMBO J 1998;17:4905-8
3. Meaney MJ, Szyf M. Maternal care as a model for experience-dependent chromatin plasticity? Trends Neurosci 2005;28:456-63
4. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007;16(Spec No 1):R50-9
5. Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-92
6. Shi B, Liang J, Yang X, et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol 2007;27:5105-19
7. Hossain A, Kuo MT, Saunders GF. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol 2006;26:8191-201
8. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89-92
9. Issa JP, Vertino PM, Wu J, et al. Increased cytosine DNA-methyltransferase activity during colon cancer progression. J Natl Cancer Inst 1993;85:1235-40
10. Oki Y, Aoki E, Issa JP. Decitabine - bedside to bench. Crit Rev Oncol Hematol 2007;61:140-52
11. Szyf M, Pakneshan P, Rabbani SA. DNA demethylation and cancer: therapeutic implications. Cancer Lett 2004;211:133-43
12. Razin A, Szyf M. DNA methylation patterns. Formation and function. Biochim Biophys Acta 1984;782:331-42
13. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007;39:457-66
14. Adams RL, Turnbull J, Smillie EJ, Burdon RH. DNA methylation in nuclei and studies using a purified DNA methylase from ascites cells. In: Antoni F, Farago A, editors, Post-synthetic modification of macromolecules. Amsterdam: North-Holland; 1975. p. 39-48
15. Wu JC, Santi DV. On the mechanism and inhibition of DNA cytosine methyltransferases. Prog Clin Biol Res 1985;198:119-29
16. Cheng X, Kumar S, Posfai J, et al. Crystal structure of the HhaI DNA methyltransferase complexed with S-adenosyl-L-methionine. Cell 1993;74:299-307
17. Gruenbaum Y, Cedar H, Razin A. Substrate and sequence specificity of a eukaryotic DNA methylase. Nature 1982;295:620-2
18. Bestor TH, Verdine GL. DNA methyltransferases. Curr Opin Cell Biol 1994;6:380-9
19. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases [letter]. Nat Genet 1998;19:219-20
20. Razin A, Kafri T. DNA methylation from embryo to adult. Prog Nucleic Acid Res Mol Biol 1994;48:53-81
21. Liang G, Chan MF, Tomigahara Y, et al. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol 2002;22:480-91
22. Kim GD, Ni J, Kelesoglu N, et al. Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. EMBO J 2002;21:4183-95
23. Hattori N, Abe T, Hattori N, et al. Preference of DNA methyltransferases for CpG islands in mouse embryonic stem cells. Genome Res 2004;14:1733-40
24. Linhart HG, Lin H, Yamada Y, et al. Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev 2007;21:3110-22
25. Fuks F, Burgers WA, Brehm A, et al. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 2000;24:88-91
26. Fuks F, Burgers WA, Godin N, et al. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J 2001;20:2536-44
27. Fuks F, Hurd PJ, Deplus R, Kouzarides T. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res 2003;31:2305-12
28. Fuks F, Hurd PJ, Wolf D, et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003;278:4035-40
29. Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 2000;25:269-77
30. Schlesinger Y, Straussman R, Keshet I, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007;39:232-6
31. Vire E, Brenner C, Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2005
32. Villa R, Pasini D, Gutierrez A, et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 2007;11:513-25
33. Brenner C, Deplus R, Didelot C, et al. Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J 2005;24:336-46
34. Burgers WA, Blanchon L, Pradhan S, et al. Viral oncoproteins target the DNA methyltransferases. Oncogene 2006;26:1650-5
35. Di Croce L, Raker VA, Corsaro M, et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002;295:1079-82
36. Yu W, Gius D, Onyango P, et al. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 2008;451:202-6
37. Bostick M, Kim JK, Esteve PO, et al. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 2007;317:1760-4
38. Wu J, Issa JP, Herman J, et al. Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells [see comments]. Proc Natl Acad Sci USA 1993;90:8891-5
39. Detich N, Ramchandani S, Szyf M. A conserved 3′-untranslated element mediates growth regulation of DNA methyltransferase 1 and inhibits its transforming activity. J Biol Chem 2001;276:24881-90
40. Vire E, Brenner C, Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439:871-4
41. Rosenbaum E, Hoque MO, Cohen Y, et al. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005;11:8321-5
42. Woodson K, O'Reilly KJ, Ward DE, et al. CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics 2006;1:183-6
43. Ellinger J, Bastian PJ, Jurgan T, et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 2008;71:161-7
44. Szyf M. DNA methylation properties: consequences for pharmacology. Trends Pharmacol Sci 1994;15:233-8
45. MacLeod AR, Szyf M. Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis. J Biol Chem 1995;270:8037-43
46. Ramchandani S, MacLeod AR, Pinard M, et al. Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 1997;94:684-9
47. Laird PW, Jackson-Grusby L, Fazeli A, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 1995;81:197-205
48. Fournel M, Sapieha P, Beaulieu N, et al. Down-regulation of human DNA-(cytosine-5) methyltransferase induces cell cycle regulators p16(ink4A) and p21(WAF/CipI) by distinct mechanisms. J Biol Chem 1999;274:24250-6
49. Milutinovic S, Knox JD, Szyf M. DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdi1). J Biol Chem 2000;275:6353-9
50. Knox JD, Araujo FD, Bigey P, et al. Inhibition of DNA methyltransferase inhibits DNA replication. J Biol Chem 2000;275:17986-90
51. Milutinovic S, Zhuang Q, Niveleau A, Szyf M. Epigenomic stress response. Knockdown of DNA methyltransferase 1 triggers an intra-S-phase arrest of DNA replication and induction of stress response genes. J Biol Chem 2003;278:14985-95
52. Unterberger A, Andrews SD, Weaver IC, Szyf M. DNA methyltransferase 1 knockdown activates a replication stress checkpoint. Mol Cell Biol 2006;26:7575-86
53. Taylor SM, Jones PA. Mechanism of action of eukaryotic DNA methyltransferase. Use of 5-azacytosine-containing DNA. J Mol Biol 1982;162:679-92
54. Davis AJ, Gelmon KA, Siu LL, et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs 2003;21:85-97
55. Winquist E, Knox J, Ayoub JP. Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs 2006;24:159-67
56. Jones PA, Taylor SM, Mohandas T, Shapiro LJ. Cell cycle-specific reactivation of an inactive X-chromosome locus by 5-azadeoxycytidine. Proc Natl Acad Sci USA 1982;79:1215-9
57. Merlo A, Herman JG, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/ CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92
58. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994;91:11797-801
59. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972;56:649-52
60. Karon M, Sieger L, Leimbrock S, et al. 5-Azacytidine: a new active agent for the treatment of acute leukemia. Blood 1973;42:359-65
61. Kuykendall JR. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders. Ann Pharmacother 2005;39:1700-9
62. Michaelis M, Doerr HW, Cinatl J Jr. Valproic acid as anti-cancer drug. Curr Pharm Des 2007;13:3378-93
63. Stegmann AP, Honders MW, Hagemeijer A, et al. In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2′-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kunase (dck) gene. Ann Hematol 1995;71:41-7
64. Detich N, Bovenzi V, Szyf M. Valproate induces replication-independent active DNA demethylation. J Biol Chem 2003;278:27586-92
65. Milutinovic S, D'Alessio AC, Detich N, Szyf M. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 2007;28:560-71
66. Cervoni N, Sang-beom S, Chakravarti D, Szyf M. A novel regulatory role for Set/TAF-Iβ oncoprotein integrating histone hypoacetylation and DNA hypermethylation in transcriptional silencing. Submitted for Publication; 2001
67. Cervoni N, Szyf M. Demethylase activity is directed by histone acetylation. J Biol Chem 2001;276:40778-87
68. Ou JN, Torrisani J, Unterberger A, et al. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol 2007;73:1297-307
69. Gius D, Cui H, Bradbury CM, et al. Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 2004;6:361-71
70. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002;21:5400-13
71. Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res 1988;48:1159-61
72. Ji W, Hernandez R, Zhang XY, et al. DNA demethylation and pericentromeric rearrangements of chromosome 1. Mutat Res 1997;379:33-41
73. Wilson MJ, Shivapurkar N, Poirier LA. Hypomethylation of hepatic nuclear DNA in rats fed with a carcinogenic methyl-deficient diet. Biochem J 1984;218:987-90
74. Bhave MR, Wilson MJ, Poirier LA. c-H-ras and c-K-ras gene hypomethylation in the livers and hepatomas of rats fed methyl-deficient, amino acid-defined diets. Carcinogenesis 1988;9:343-8
75. Kanduc D, Ghoshal A, Quagliariello E, Farber E. DNA hypomethylation in ethionine-induced rat preneoplastic hepatocyte nodules. Biochem Biophys Res Commun 1988;150:739-44
76. Pascale RM, Simile MM, De Miglio MR, Feo F. Chemoprevention of hepatocarcinogenesis: S-adenosyl-L-methionine. Alcohol 2002;27:193-8
77. Lu SC, Huang ZZ, Yang H, et al. Changes in methionine adenosyltransferase and S-adenosylmethionine homeostasis in alcoholic rat liver. Am J Physiol Gastrointest Liver Physiol 2000;279:G178-85
78. Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 1993;85:875-84
79. Potter JD. Methyl supply, methyl metabolizing enzymes and colorectal neoplasia. J Nutr 2002;132:2410S-2412S
80. Ryan BM, Weir DG. Relevance of folate metabolism in the pathogenesis of colorectal cancer. J Lab Clin Med 2001;138:164-76
81. Suzuki T, Matsuo K, Hasegawa Y, et al. One-carbon metabolism-related gene polymorphisms and risk of head and neck squamous cell carcinoma: case-control study. Cancer Sci 2007;98:1439-46
82. Suzuki T, Matsuo K, Hiraki A, et al. Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a case control study. Carcinogenesis 2007;28:1718-25
83. Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science 2003;300:489-92
84. Chen RZ, Pettersson U, Beard C, et al. DNA hypomethylation leads to elevated mutation rates. Nature 1998;395:89-93
85. Lu LJ, Randerath K. Long term instability and molecular mechanism of 5-azacytidine-induced DNA hypomethylation in normal and neoplastic tissues in vivo. Mol Pharmacol 1984;26:594-603
86. Howard G, Eiges R, Gaudet F, et al. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 2007;27:404-8
87. Han L, Witmer PD, Casey E, et al. DNA Methylation Regulates MicroRNA Expression. Cancer Biol Ther 2007;6
88. Cheah MS, Wallace CD, Hoffman RM. Hypomethylation of DNA in human cancer cells: a site-specific change in the c-myc oncogene. J Natl Cancer Inst 1984;73:1057-65
89. Kaneko Y, Shibuya M, Nakayama T, et al. Hypomethylation of c-myc and epidermal growth factor receptor genes in human hepatocellular carcinoma and fetal liver. Jpn J Cancer Res 1985;76:1136-40
90. Lipsanen V, Leinonen P, Alhonen L, Janne J. Hypomethylation of omithine decarboxylase gene and erb-A1 oncogene in human chronic lymphatic leukemia. Blood 1988;72:2042-4
91. Howard G, Eiges R, Gaudet F, et al. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 2007
92. Weber J, Salgaller M, Samid D, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res 1994;54:1766-71
93. Hofbauer GF, Schaefer C, Noppen C, et al. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol 1997;151:1549-53
94. Roeder C, Schuler-Thurner B, Berchtold S, et al. MAGE-A3 is a frequent tumor antigen of metastasized melanoma. Arch Dermatol Res 2005;296:314-9
95. Nishimura S, Fujita M, Terata N, et al. Expression of MAGE genes in colorectal carcinomas. Nihon Rinsho Meneki Gakkai Kaishi 1997;20:95-101
96. Kavalar R, Sarcevic B, Spagnoli GC, et al. Expression of MAGE tumour-associated antigens is inversely correlated with tumour differentiation in invasive ductal breast cancers: an immunohistochemical study. Virchows Arch 2001;439:127-31
97. Hansel DE, House MG, Ashfaq R, et al. MAGE1 is expressed by a subset of pancreatic endocrine neoplasms and associated lymph node and liver metastases. Int J Gastrointest Cancer 2003;33:141-7
98. Honda T, Tamura G, Waki T, et al. Demethylation of MAGE promoters during gastric cancer progression. Br J Cancer 2004;90:838-43
99. Ormerod EJ, Everett CA, Hart IR. Enhanced experimental metastatic capacity of a human tumor line following treatment with 5-azacytidine. Cancer Res 1986;46:884-90
100. Gupta A, Godwin AK, Vanderveer L, et al. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 2003;63:664-73
101. Nakamura N, Takenaga K. Hypomethylation of the metastasis-associated S100A4 gene correlates with gene activation in human colon adenocarcinoma cell lines. Clin Exp Metastasis 1998;16:471-9
102. Rosty C, Ueki T, Argani P, et al. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol 2002;160:45-50
103. Mori T, Kim J, Yamano T, et al. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 2005;65:1800-7
104. Shukeir N, Pakneshan P, Chen G, et al. Alteration of the Methylation Status of Tumor-Promoting Genes Decreases Prostate Cancer Cell Invasiveness and Tumorigenesis In vitro and In vivo. Cancer Res 2006;66:9202-10
105. Guo Y, Pakneshan P, Gladu J, et al. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. J Biol Chem 2002;277:41571-9
106. Pakneshan P, Xing RH, Rabbani SA. Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo. FASEB J 2003;17:1081-8
107. Pakneshan P, Szyf M, Farias-Eisner R, Rabbani SA. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J Biol Chem 2004;279:31735-44
108. Shteper PJ, Zcharia E, Ashhab Y, et al. Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene 2003;22:7737-49
109. Ateq B, Unterberger A, Rabbani SA, Szyf M. Pharmacological inhibition of dna methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 2008;10:1-13
110. Pakneshan P, Szyf M, Rabbani SA. Methylation and inhibition of uPA expression by RAS oncogene divergence of growth control and invasion in breast cancer cells. Carcinogenesis 2004
111. Sun Y, Hegamyer G, Kim H, et al. Molecular cloning of mouse tissue inhibitor of metalloproteinases-3 and its promoter. Specific lack of expression in neoplastic JB6 cells may reflect altered gene methylation. J Biol Chem 1995;270:19312-9
112. Fidler IJ. Understanding bone metastases: the key to the effective treatment of prostate cancer. Clin Adv Hematol Oncol 2003;1:278-9
113. Yu Q, Thieu VT, Kaplan MH. Stat4 limits DNA methyltransferase recruitment and DNA methylation of the IL-18Ralpha gene during Th1 differentiation. EMBO J 2007
114. Jost JP, Oakeley EJ, Zhu B, et al. 5-Methylcytosine DNA glycosylase participates in the genome-wide loss of DNA methylation occurring during mouse myoblast differentiation. Nucleic Acids Res 2001;29:4452-61
115. Zhu B, Zheng Y, Hess D, et al. 5-methylcytosine-DNA glycosylase activity is present in a cloned G/T mismatch DNA glycosylase associated with the chicken embryo DNA demethylation complex. Proc Natl Acad Sci USA 2000;97:5135-9
116. Zhu B, Zheng Y, Angliker H, et al. 5-Methylcytosine DNA glycosylase activity is also present in the human MBD4 (G/T mismatch glycosylase) and in a related avian sequence. Nucleic Acids Res 2000;28:4157-65
117. Barreto G, Schafer A, Marhold J, et al. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 2007
118. Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M. A mammalian protein with specific demethylase activity for mCpG DNA. Nature 1999;397:579-83
119. Ng HH, Zhang Y, Hendrich B, et al. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet 1999;23:58-61
120. Zhang Y, Ng HH, Erdjument-Bromage H, et al. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 1999;13:1924-35
121. Angrisano T, Lembo F, Pero R, et al. TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters. Nucleic Acids Res 2006;34:364-72
122. Ego T, Tanaka Y, Shimotohno K. Interaction of HTLV-1 Tax and methyl-CpG-binding domain 2 positively regulates the gene expression from the hypermethylated LTR. Oncogene 2005;24:1914-23
123. Lembo F, Pero R, Angrisano T, et al. MBDin, a novel MBD2-interacting protein, relieves MBD2 repression potential and reactivates transcription from methylated promoters. Mol Cell Biol 2003;23:1656-65
124. Detich N, Hamm S, Just G, et al. The methyl donor S-adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-adenosylmethionine. J Biol Chem 2003;278:20812-20
125. Detich N, Theberge J, Szyf M. Promoter-specific activation and demethylation by MBD2/demethylase. J Biol Chem 2002;277:35791-4
126. Balada E, Ordi-Ros J, Serrano-Acedo S, et al. Transcript overexpression of the MBD2 and MBD4 genes in CD4+ T cells from systemic lupus erythematosus patients. J Leukoc Biol 2007
127. Slack A, Bovenzi V, Bigey P, et al. Antisense MBD2 gene therapy inhibits tumorigenesis. J Gene Med 2002;4:381-9
128. Campbell PM, Bovenzi V, Szyf M. Methylated DNA-binding protein 2 antisense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo. Carcinogenesis 2004;25:499-507
129. Sansom OJ, Berger J, Bishop SM, et al. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat Genet 2003;34:145-7
130. Appleton K, Mackay HJ. Judson I, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007;25:4603-9
131. Milutinovic S, Brown SE, Zhuang Q, Szyf M. DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation. J Biol Chem 2004;279:27915-27
132. Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann Oncol 2002;13:1699-716
133. Stewart DJ, Donehower RC, Eisenhauer EA, et al. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol 2003;14:766-74
134. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985;228:187-90
135. Bernardino J, Roux C, Almeida A, et al. DNA hypomethylation in breast cancer: an independent parameter of tumor progression? Cancer Genet Cytogenet 1997;97:83-9